Nadeem Sarwar, President, Center for Genetics Guided Dementia discovery (G2D2), Eisai
Nadeem’s expertise stems from the intersection of genomics and data sciences with collaborative business models for therapeutic discovery. He is the Founder and President of the Eisai Center for Genetics Guided Dementia Discovery (G2D2), with past executive experience in academia (Tenured Faculty, University of Cambridge), big-pharma (Senior Director, Pfizer), mid-sized pharma (VP, Eisai), and Biotech (G2D2).
Current role: Within Eisai, Nadeem has established three incremental new organizations. First, as VP and Global Head of Genetics & Human Biology, created the Integrated Human Genomics (IHGx) department, to provide human genetics support to all programs across Eisai’s pipeline. Second, as President of the Eisai AiM Institute (Andover, MA), AiM progressed two assets (E7046: immuno-oncology [partnered]; E6742: SLE) through Phase 1, discovered a new immunotherapy (E7766: IND filed), and introduced a new R&D theme in immunodementia. Finally, built upon the success of AiM, his current role is as Founder and President of G2D2: an autonomous “spin-in” biotech exclusively focused on harnessing human genetics, data sciences and precision chemistry. G2D2’s primary focus is immunodementia: genetically validated immune targets for dementia. It is located at a new, tailored-designed 50,000 Sqft facility in Cambridge, MA. The facility was designed and constructed under Nadeem’s leadership, including the new Eisai Incubator for NeuroDiscovery (to enable Cambridge-based start-ups conducting high-risk science with potential to disrupt neuro-drug discovery).
Previous roles: Before joining Eisai, Nadeem was Senior Director, Head of Population Research & Head of Cardiometabolic Genetics, at Pfizer Inc. Prior to working in the pharmaceutical industry, Nadeem was tenured faculty at the School of Clinical Medicine, University of Cambridge (UK). His research involved establishment of several large-scale bioresources including: The Emerging Risk Factors Collaboration (2M participants); Generation Scotland (50K); The Pakistan Risk of Myocardial Infarction Study (50K); and the Botswana Pelo & HIV Initiative (1K).